GI
TXG icon

Gradient Investments’s 10x Genomics TXG Stock Holding History

Gradient Investments’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-25
Closed -$1.4K – 1910
2023
Q2 		$1.4K Hold
25
– – ﹤0.01% 1265
2023
Q1 		$1.4K Hold
25
– – ﹤0.01% 1155
2022
Q4 		$911 Hold
25
– – ﹤0.01% 1211
2022
Q3 		$1K Hold
25
– – ﹤0.01% 1301
2022
Q2 		$1K Hold
25
– – ﹤0.01% 1175
2022
Q1 		$2K Hold
25
– – ﹤0.01% 1067
2021
Q4 		$4K Buy
+25
New +$3.83K ﹤0.01% 984

Other funds holding TXG

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Gradient Investments's TXG Position: Q3 2023 in Review

Gradient Investments sold out of 10x Genomics (TXG) in Q3 2023, closing a stake of 25 shares — an estimated $1.4K sold.

Gradient Investments first reported a position in TXG in Q4 2021 and held it in 7 quarters. The position peaked at $4K in Q4 2021. 256 funds tracked by Wall St. Rank hold TXG as of Q3 2023.

  • Gradient Investments reported no remaining 10x Genomics position as of Q3 2023 after selling out during the quarter.
  • Gradient Investments sold 25 10x Genomics shares in Q3 2023, an estimated $1.4K.
  • Gradient Investments first reported a position in 10x Genomics in Q4 2021 and held it in 7 quarters.
  • Gradient Investments's 10x Genomics position peaked at $4K in Q4 2021.
  • 256 funds tracked by Wall St. Rank held 10x Genomics as of Q3 2023.

Based on Gradient Investments's 13F filing for Q3 2023, filed 27 Oct 2023.